Report of Two Cases of Carbamazepine-Induced DRESS Syndrome Report of Two Cases of Carbamazepine-Induced DRESS Syndrome
Two pediatric patients who presented with suspected MIS-C were later diagnosed with DRESS syndrome associated with the use of carbamazepine.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2022 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
Self-injury with carbamazepine intoxication in an elementary school-aged child - Shieh A, Schellpfeffer N.
We describe the case of a 9-year-old female who presented with acute altered mental status and respiratory failure requiring ... (Source: SafetyLit)
Source: SafetyLit - June 13, 2022 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Severe carbamazepine toxicity treated with continuous venovenous hemofiltration at Palestine medical complex: two case reports - Nasif MA, Falana HH, Hamed HKH, Yousef QGH, Jaradat MA.
Carbamazepine intoxication is not uncommon and accounts for many cases of poisoning among anticonvulsive medications users. Since there is no specific antidote for carbamazepine overdose, management is limited to gastric decontamination and supportive ther... (Source: SafetyLit)
Source: SafetyLit - April 27, 2022 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first ...
Source: Johnson and Johnson - March 30, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
TITUSVILLE, N.J., March 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label update for CABENUVA (cabotegravir and rilpivirine), giving healthcare professionals and people living with human immunodeficiency virus (HIV-1) in the U.S. the option to start this once-monthly or every-two-month injectable treatment without the need for the oral lead-in phase (daily cabotegravir and rilpivirine tablets, taken for one month prior to initiation of cabotegravir and rilpivirine injections).1 Clinical data demonstrated the regimen di...
Source: Johnson and Johnson - March 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Widely Used Antiepileptic Tied to Lower Vitamin D Levels Widely Used Antiepileptic Tied to Lower Vitamin D Levels
The widely used antiepileptic medication carbamazepine is associated with lower vitamin D levels, highlighting the need for regular monitoring of patients who take the drug.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 15, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
NPPA approves price rise of 50 per cent for carbamazepine, ranitidine, ibuprofen
NPPA, in its meeting on June 28, deliberated upon the case of upward price revision of the formulations of these drugs under Para 19 of DPCO 2013 and noted that the scheduled formulations being considered for upward price revision are low-priced drugs and have been under repeated price controls, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 2, 2021 Category: Pharmaceuticals Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both monthly dosing an...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a stable regimen,...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Carbamazepine for irritability and aggression after traumatic brain injury: a randomized, placebo-controlled study - Hammond FMC, Zafonte RD, Tang Q, Jang JH.
This study tested the hypothesis that carbamazepine (CBZ) reduces irritability/aggression among individuals> 6 months post-traumatic brain injury (TBI). 70 individuals were enrolled in a parallel-group, randomized, double-blind, placebo-controlled, forced... (Source: SafetyLit)
Source: SafetyLit - February 15, 2021 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces Health Canada Approval of CABENUVA ™, the First Long-Acting Regimen for the Treatment of HIV
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with two separate inj...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Overdose of carbamazepine before hanging by a child: a case report of a complex suicide - Vadysinghe AN, Thilakarathne SMNK.
Compared to death by hanging, fatal cases due to carbamazapine intake is hardly seen. We are reporting a rare case where the victim had used this combination to terminate life as a complex suicide.
Language: en... (Source: SafetyLit)
Source: SafetyLit - October 2, 2019 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
